Kailera Therapeutics, Inc.
NASDAQ:KLRABiotechnology
+$0.51 today
- Market cap
- $1.53B
- Beta
- 0.00
Volume 0.42M
Average 0.80M
KLRA Capital Expenditures
Cash spent on property, plant, equipment, and other long-term assets.
Kailera Therapeutics, Inc.NASDAQ: KLRA
Capital Expenditures · Q2 FY2026 · quarter ended Jun 2026
Capital expenditures of $0 in Q2 FY2026
Q2 FY2026 capital expenditures was $0.
Sources:Cash FlowText generated from reported figures; not investment advice.
Capital Expenditures history
USD · from the cash flow
- Latest · FY2025
- (2.09M) USD
- Year-over-year change
- —
| Period | Period end | Capital Expenditures | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (2.09M) | — |
Capital Expenditures vs competitors
How KLRA compares with its peers on the latest reported figures
- KLRA's FY2025 capital expenditures of $2.09M is the 2nd largest of the 10 companies compared; the peer median is $32K.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
MBXMBX Biosciences, Inc. Common Stock | LTM Sep 2026 | $3.32M | +170.5% | +63.5% | — |
KLRAKailera Therapeutics, Inc. | FY2025 | $2.09M | — | — | — |
BIOABioAge Labs, Inc. | LTM Mar 2026 | $319K | -59.7% | +91.1% | 3.1% |
| LTM Jun 2026 | $260K | +42.9% | +3.6% | 3.7% | |
| LTM Mar 2026 | $192.68K | +1114.8% | +57.4% | — | |
| LTM Mar 2026 | $109K | -90.6% | +115.1% | — | |
| LTM Mar 2026 | $32K | — | -55.6% | 88.9% | |
| LTM Jun 2026 | $0 | — | — | — | |
| LTM Mar 2026 | $0 | — | — | 0.0% | |
| LTM Mar 2026 | $0 | +100.0% | — | — | |
| Peer median (excluding KLRA) | $32K | +71.4% | +60.5% | 3.4% | |
Competitors are the stored peer set for KLRA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2025 Dec 2025 |
|---|---|
| Net Income | (148.96M) |
| Depreciation & Amortization | 310K |
| Deferred Income Tax | 0 |
| Stock-Based Compensation | 10.94M |
| Change in Working Capital | 16.78M |
| Accounts Receivables | 0 |
| Inventory | 0 |
| Accounts Payables | 4.69M |
| Other Working Capital | 12.09M |
| Other Non-Cash Items | 714K |
| Operating Cash Flow | (120.21M) |
| Capital Expenditures | (2.09M) |
| Acquisitions (Net) | 0 |
| Purchases of Investments | (632.16M) |
| Sales of Investments | 141.65M |
| Other Investing Activities | 0 |
| Investing Cash Flow | (492.6M) |
| Debt Repayment | 100M |
| Common Stock Issued | 498.97M |
| Common Stock Repurchased | 0 |
| Dividends Paid | 0 |
| Other Financing Activities | (499.19M) |
| Financing Cash Flow | 598.66M |
| Effect of Forex Changes | 0 |
| Net Change in Cash | (14.15M) |
| Free Cash Flow | (122.3M) |
Kailera Therapeutics, Inc.
NASDAQ:KLRA
Intrinsic Alpha fair value
Locked
Current Price
$11.79
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.